Immunovaccine Receives an Extension to the Maturity Date of its $5M Loan Until 2020
"Maintaining a strong financial position is a critical step for our organization as we make this important transition into a later-clinical stage life sciences company," said Pierre Labbé, Chief Financial Officer of
"As we approach the anticipated topline data from our Phase 1 clinical trial with
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals.
T: (312) 961-2502 E: firstname.lastname@example.org
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: email@example.com
O: (415) 513-1284
T: (415) 515-4572 E: firstname.lastname@example.org
Source: Immunovaccine Inc.